Benzinga | Feb 3, 2021 08:36AM EST

BioCryst Gains After FDA Nod For Expanded Use of RAPIVAB

* BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) shares jump after the FDA approved supplemental marketing application seeking approval for RAPIVAB (peramivir injection) to treat acute uncomplicated influenza to include patients six months and older who have been symptomatic for no more than two days.

* Before this approval, RAPIVAB had been indicated for patients two years and older.

* BCRX shares gained 7.03% at $11.27 pre-market on the last check Wednesday.